Actuate Therapeutics Launches GSK-3beta Inhibitor Research Initiative
Actuate Therapeutics announced the launch of an expanded research initiative evaluating combinations of its clinical-stage GSK-3beta inhibitor elraglusib with emerging RAS-targeted therapies. Despite recent advances in RAS-targeted therapies, adaptive resistance mechanisms and pathway reactivation remain some of the key barriers to achieving durable responses in patients. Based on the mechanisms of action, GSK-3 inhibition may represent a critical complementary strategy capable of enhancing RAS-targeted therapies by suppressing downstream survival signaling and resistance pathways, including NF-kB-mediated survival signaling; MYC-driven transcriptional programs; metabolic adaptation and oxidative stress buffering; tumor microenvironment immune suppression. In addition, RAS-mutant tumors - particularly pancreatic cancer - are widely considered immunologically resistant. Preclinical research suggests that GSK-3beta inhibition may enhance antigen presentation, activate T cells and NK cells, and reduce exhausted T-cells. By simultaneously targeting tumor intrinsic survival pathways and modulating the tumor immune microenvironment, the combination of elraglusib and RAS inhibitors has the potential to create a multi-modal therapeutic strategy designed to overcome resistance and expand clinical benefit in RAS-driven cancers.
